Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RALPH JONATHAN HENDERSON

Allopathic & Osteopathic Physicians Urology

NPI
1164427621
CMS profile
681317
Location
SHREVEPORT, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$24,443.77

81 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RALPH JONATHAN HENDERSON

NPI 1164427621 · CMS profile ID 681317

Allopathic & Osteopathic Physicians / Urology

SHREVEPORT, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1164427621?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RALPH JONATHAN HENDERSON, NPI 1164427621, CMS profile ID 681317. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1164427621?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). RALPH JONATHAN HENDERSON, NPI 1164427621, CMS profile ID 681317. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1164427621?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
RALPH JONATHAN HENDERSON, NPI 1164427621, CMS profile ID 681317, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1164427621?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

81 matching records · $24,443.77 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 81 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–81 of 81.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $17.8406/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078684055 CMS
Sumitomo Pharma America, Inc. $3.9206/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148863515 CMS
Novartis Pharmaceuticals Corporation $19.9106/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086859821 CMS
Janssen Biotech, Inc. $149.6606/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078682895 CMS
Sumitomo Pharma America, Inc. $120.1106/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148863513 CMS
Janssen Biotech, Inc. $1,100.0005/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078684815 CMS
Verity Pharmaceuticals Inc. $24.7505/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080607442 CMS
Sumitomo Pharma America, Inc. $20.8704/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148863511 CMS
Sumitomo Pharma America, Inc. $25.1904/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148863509 CMS
PFIZER INC. $16.4104/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130909426 CMS
Janssen Biotech, Inc. $550.0004/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078684817 CMS
Novartis Pharmaceuticals Corporation $22.6904/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086859815 CMS
UROGEN PHARMA, INC. $12.0103/27/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137922841 CMS
UROGEN PHARMA, INC. $1,250.0003/26/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137918273 CMS
Sumitomo Pharma America, Inc. $23.6803/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148863507 CMS
Verity Pharmaceuticals Inc. $29.1703/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080607451 CMS
ABBVIE INC. $17.3303/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103903896 CMS
Dendreon Pharmaceuticals LLC $154.7403/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149316966 CMS
PFIZER INC. $15.7503/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130901964 CMS
Novartis Pharmaceuticals Corporation $22.6902/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086859813 CMS
Sumitomo Pharma America, Inc. $5.9102/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148863505 CMS
Myriad Genetic Laboratories, Inc. $79.7402/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152532520 CMS
Sumitomo Pharma America, Inc. $108.9302/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148863501 CMS
Sumitomo Pharma America, Inc. $16.2302/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148863503 CMS
Sumitomo Pharma America, Inc. $73.5202/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148863499 CMS
Janssen Biotech, Inc. $825.0001/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078684709 CMS
Sumitomo Pharma America, Inc. $17.9801/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148863497 CMS
Verity Pharmaceuticals Inc. $18.2001/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080607438 CMS
Janssen Biotech, Inc. $1,100.0001/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078683482 CMS
Sumitomo Pharma America, Inc. $21.8701/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148863495 CMS
PFIZER INC. $17.9501/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130893637 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $58,070.58 125
PY2020 $7,807.46 19
PY2021 $29,252.28 45
PY2022 $43,066.43 77
PY2023 $28,810.27 65
PY2024 $24,443.77 81
PY2025 $19,422.41 65

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $548,548.25 69
PY2024 Principal investigator $1,180,290.05 117
PY2023 Principal investigator $174,462.66 23
PY2022 Principal investigator $45,668.00 20
PY2021 Principal investigator $1,064,527.24 102
PY2020 Recipient $72.50 1
PY2020 Principal investigator $328,338.15 92
PY2019 Principal investigator $434,065.39 93

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

69 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $35,071.00 12/29/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175420653
Principal investigator 1 Ortho-Clinical Diagnostics, Inc. $31,200.00 12/29/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER LLC
VITROS Immunodiagnostic Products Total PSA III Aid in Management Intended Use Sample Collection, No dispute reported 06/30/2026 1249804386
Principal investigator 1 Janssen Research & Development, LLC $2,112.50 12/16/2025 Non-covered Recipient Entity
Arkansas Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175164174
Principal investigator 1 Janssen Research & Development, LLC $510.00 12/15/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175420799
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 12/15/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175420883
Principal investigator 1 Janssen Research & Development, LLC $3,173.00 12/09/2025 Non-covered Recipient Entity
Arkansas Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175164437
Principal investigator 1 Janssen Research & Development, LLC $1,020.00 12/01/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175420664
Principal investigator 1 Janssen Research & Development, LLC $3,390.00 12/01/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175420688
Principal investigator 1 Janssen Research & Development, LLC $6,385.00 12/01/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175420908
Principal investigator 1 PFIZER INC. $1,980.50 11/14/2025 Non-covered Recipient Entity
Arkansas Urology Research
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER No dispute reported 06/30/2026 1228728703
Principal investigator 1 Janssen Research & Development, LLC $2,102.00 11/03/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175420713
Principal investigator 1 Janssen Research & Development, LLC $13,675.00 11/03/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175420834
Principal investigator 1 Janssen Research & Development, LLC $2,728.00 11/03/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175420871
Principal investigator 1 Janssen Research & Development, LLC $1,020.00 11/03/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175420991
Principal investigator 1 Janssen Research & Development, LLC $3,173.00 10/28/2025 Non-covered Recipient Entity
Arkansas Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175164384
Principal investigator 1 Janssen Research & Development, LLC $1,760.00 10/24/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations No dispute reported 06/30/2026 1175420898
Principal investigator 1 Janssen Research & Development, LLC $6,385.00 10/17/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175420700
Principal investigator 1 Janssen Research & Development, LLC $3,390.00 10/06/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175420693
Principal investigator 1 Janssen Research & Development, LLC $3,323.00 10/02/2025 Non-covered Recipient Entity
Arkansas Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175164624
Principal investigator 1 Janssen Research & Development, LLC $10,564.00 10/02/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175420918
Principal investigator 1 PFIZER INC. $7,920.95 09/16/2025 Non-covered Recipient Entity
Arkansas Urology Research
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER No dispute reported 06/30/2026 1228761421
Principal investigator 1 Janssen Research & Development, LLC $6,385.00 09/15/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175420659
Principal investigator 1 Janssen Research & Development, LLC $17,889.00 09/15/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175420772
Principal investigator 1 Janssen Research & Development, LLC $25,596.00 09/08/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175420760
Principal investigator 1 Janssen Research & Development, LLC $2,112.50 09/05/2025 Non-covered Recipient Entity
Arkansas Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175164151
Principal investigator 1 Janssen Research & Development, LLC $9,826.00 08/14/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175420809
Principal investigator 1 PFIZER INC. $10,556.00 07/30/2025 Non-covered Recipient Entity
Arkansas Urology Research
A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF PF06821497 MEVROMETOSTAT WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER MEVPRO2 No dispute reported 06/30/2026 1228772390
Principal investigator 1 Janssen Research & Development, LLC $19,336.00 07/28/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175420669
Principal investigator 1 Janssen Research & Development, LLC $15,010.00 07/04/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175420827
Principal investigator 1 Janssen Scientific Affairs, LLC $24,250.00 07/02/2025 Non-covered Recipient Entity
Arkansas Urology-Little Rock
Validating The Guidelines-Based Care Pathway For Prostate Cancer No dispute reported 06/30/2026 1174940966
Principal investigator 1 PFIZER INC. $3,018.00 06/27/2025 Non-covered Recipient Entity
Arkansas Urology Research
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER No dispute reported 06/30/2026 1228778605
Principal investigator 1 Janssen Research & Development, LLC $510.00 06/20/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175420942
Principal investigator 1 Janssen Research & Development, LLC $2,145.00 06/16/2025 Non-covered Recipient Entity
Arkansas Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175164376
Principal investigator 1 PFIZER INC. $522.50 06/14/2025 Non-covered Recipient Entity
Arkansas Urology Research
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER No dispute reported 06/30/2026 1228792336
Principal investigator 1 Janssen Research & Development, LLC $3,390.00 06/09/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175420815
Principal investigator 1 Janssen Research & Development, LLC $24,378.00 06/06/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca No dispute reported 06/30/2026 1175420737
Principal investigator 1 Janssen Research & Development, LLC $170.00 06/02/2025 Non-covered Recipient Entity
Arkansas Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175164536
Principal investigator 1 Janssen Research & Development, LLC $125.00 06/02/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175420921
Principal investigator 1 Janssen Research & Development, LLC $510.00 05/22/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175420725
Principal investigator 1 Janssen Research & Development, LLC $8,826.00 05/22/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175420766
Principal investigator 1 Janssen Research & Development, LLC $13,385.00 05/22/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175420877
Principal investigator 1 IBSA Institut Biochimique SA $2,000.00 05/14/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A multi-center, prospective, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical trial of Sildenafil oral film 25 mg, 50 mg, 75 mg and 100 mg for the treatment of erectile dysfunction (ED) No dispute reported 06/30/2026 1223439063
Principal investigator 1 Janssen Research & Development, LLC $1,770.00 05/12/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175420720
Principal investigator 1 Janssen Research & Development, LLC $15,489.00 05/12/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175420732
Principal investigator 1 Janssen Research & Development, LLC $5,519.00 05/01/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175420965
Principal investigator 1 PFIZER INC. $2,115.50 04/29/2025 Non-covered Recipient Entity
Arkansas Urology Research
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER No dispute reported 06/30/2026 1228780439
Principal investigator 1 Janssen Research & Development, LLC $3,173.00 04/28/2025 Non-covered Recipient Entity
Arkansas Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175164351
Principal investigator 1 Janssen Research & Development, LLC $1,843.50 04/28/2025 Non-covered Recipient Entity
Arkansas Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175164513
Principal investigator 1 Janssen Research & Development, LLC $34,801.00 04/28/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175420749
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 04/11/2025 Non-covered Recipient Entity
Arkansas Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175164571
Principal investigator 1 Janssen Research & Development, LLC $25,082.00 04/07/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175420682
Principal investigator 1 Janssen Research & Development, LLC $3,687.00 04/04/2025 Non-covered Recipient Entity
Arkansas Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175164711
Principal investigator 1 PFIZER INC. $472.50 03/28/2025 Non-covered Recipient Entity
Arkansas Urology Research
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER No dispute reported 06/30/2026 1228797278
Principal investigator 1 Janssen Research & Development, LLC $1,020.00 03/14/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175420972
Principal investigator 1 Janssen Research & Development, LLC $510.00 03/13/2025 Non-covered Recipient Entity
Arkansas Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175164688
Principal investigator 1 Janssen Research & Development, LLC $14,117.00 03/13/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175420792
Principal investigator 1 Janssen Research & Development, LLC $13,762.00 03/10/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175420708
Principal investigator 1 Janssen Research & Development, LLC $6,634.00 03/07/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175420784
Principal investigator 1 Janssen Research & Development, LLC $510.00 02/24/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175420845
Principal investigator 1 PFIZER INC. $1,128.60 02/20/2025 Non-covered Recipient Entity
Arkansas Urology
A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF PF06821497 MEVROMETOSTAT WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER MEVPRO2 No dispute reported 06/30/2026 1228725514
Principal investigator 1 PFIZER INC. $853.20 02/20/2025 Non-covered Recipient Entity
Arkansas Urology
A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF PF06821497 MEVROMETOSTAT WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER MEVPRO2 No dispute reported 06/30/2026 1228733348
Principal investigator 1 Janssen Research & Development, LLC $1,750.00 02/13/2025 Non-covered Recipient Entity
Arkansas Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175164591
Principal investigator 1 Janssen Research & Development, LLC $1,279.00 02/12/2025 Non-covered Recipient Entity
Arkansas Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175164462
Principal investigator 1 Janssen Research & Development, LLC $27,532.00 02/10/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175420840
Principal investigator 1 Janssen Research & Development, LLC $3,455.00 02/10/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175420904
Principal investigator 1 PFIZER INC. $10,900.00 01/25/2025 Non-covered Recipient Entity
Arkansas Urology Research
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER No dispute reported 06/30/2026 1228801572
Principal investigator 1 Ferring Pharmaceuticals AS $5,000.00 01/23/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER LLC
A Phase 4, Multi-center, Open Label Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose No dispute reported 06/30/2026 1242060116
Principal investigator 1 Janssen Research & Development, LLC $1,092.00 01/13/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM No dispute reported 06/30/2026 1175420891
Principal investigator 1 Janssen Research & Development, LLC $30,730.00 01/02/2025 Non-covered Recipient Entity
ARKANSAS UROLOGY RESEARCH CENTER
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175420997

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2024 Amount invested $0.00 2
PY2024 Value of interest $75,352.94 2
PY2023 Amount invested $0.00 1
PY2023 Value of interest $73,877.15 1
PY2022 Amount invested $0.00 1
PY2022 Value of interest $35,664.83 1
PY2021 Amount invested $0.00 1
PY2021 Value of interest $33,117.34 1
PY2020 Amount invested $0.00 1
PY2020 Value of interest $84,916.31 1
PY2019 Amount invested $0.00 1
PY2019 Value of interest $64,952.25 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

7 records · PY2019–2024

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2024 SN Holdings, LLC $0.00 $192.07 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124771469
PY2024 SN Holdings, LLC $0.00 $75,160.87 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124773217
PY2023 SN Holdings, LLC $0.00 $73,877.15 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1032887233
PY2022 SN Holdings, LLC $0.00 $35,664.83 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 941609231
PY2021 SN Holdings, LLC $0.00 $33,117.34 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 820124965
PY2020 UroGPO LLC $0.00 $84,916.31 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 737139477
PY2019 UroGPO LLC $0.00 $64,952.25 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 690775057